We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 466

Justice Department Allots Additional US$70 Million to Battle Opioid Crisis
  • Squire Patton Boggs
  • USA
  • November 7 2018

In tandem with President Trump’s signing of H.R. 6, (now former) US Attorney General Jeff Sessions announced new Department of Justice (DOJ) funding


The SUPPORT for Patients and Communities Act: Expanding Medicare Coverage of Telehealth Services to Combat the Opioid Crisis
  • Epstein Becker Green
  • USA
  • November 5 2018

The SUPPORT for Patients and Communities Act (“the Act” or “the SUPPORT Act”), signed into law by President Trump on October 24, 2018, is intended to


The U.S. Department of Health and Human Services Launches New Opioid-Related Initiatives
  • Dykema Gossett PLLC
  • USA
  • November 2 2018

Following President Trump’s signature on broad federal legislation to combat the opioid crisis in the U.S., the U.S. Department of Health and Human


Federal government takes steps toward ubiquity of cannabis drugs
  • Reed Smith LLP
  • USA
  • November 1 2018

The federal government finally seems ready to acknowledge the potential advantages of medicinal CBD and marijuana-derived medication. The Food and


How SUPPORT Will Affect Pharma Interactions With DEA
  • Cadwalader Wickersham & Taft LLP
  • USA
  • October 31 2018

The opioid package President Donald Trump signed last week garnered much attention. While it is largely directed at treatment and prevention, it


The Feds and New York Allow Further Access to CBD and Medical Cannabis
  • Wilson Elser
  • USA
  • October 24 2018

On September 28, 2018, the Drug Enforcement Administration (DEA) took the long-awaited step of rescheduling Epidiolex - the first FDA-approved drug


DEA to Propose Significant Regulatory Changes in the Coming Year
  • Quarles & Brady LLP
  • USA
  • October 23 2018

The Department of Justice recently published its list of proposed regulatory actions for the near and long term. It appears that the Drug Enforcement


6th Circ. Ruling Highlights Dangers Of Insured's Admissions
  • Jenner & Block LLP
  • USA
  • October 17 2018

The Sixth Circuit’s recent decision in K.V.G. Properties, Inc. v. Westfield Insurance Co.underscores that an insured’s admissions in non-insurance


The DEA Affirms CBD Derived from “Marijuana” Is Federally Unlawful
  • Duane Morris LLP
  • USA
  • October 12 2018

The Controlled Substances Act defines “marijuana” as: all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin


The Long-Awaited Telemedicine Controlled Substance Prescribing Permit
  • Bryan Cave Leighton Paisner LLP
  • USA
  • October 11 2018

Last week, the United States Congress passed a 250-page bill addressing the opioid crisis entitled SUPPORT for Patients and Communities Act (the